Major Histocompatibility Complex 2017; 24 (2): 150 157 抄録集 1 HLA 2017 5 13 150
1 HLA MHC 2017; 24 (2) HLA 1960 1964 HLA 1967 HLA HLA HLA HLA 1980 HLA HLA ABO HLA 2000 HLA DSA 2010 HLA HLA HLA HLA HLA HLA HLA HLA HLA GVHD HLA HLA HLA HLA 151
MHC 2017; 24 (2) 1 HLA QCWS 2) QCWS 2) MHC HLA QC QC HLA Quality Control Workshop QCWS DNA DNA 1997 2004 QCWS 29 QCWS HLA HLA HLA T antibody mediated rejection: ABMR 1980 ABMR donor specific antibody: DSA de novo DSA ABMR 152
1 HLA MHC 2017; 24 (2) HLA HLA HLA GVHD HLA / HLA HLA HLA DSA HLA HLA1 HLA HLA PT/Cy HLA HLA-A -B -DRB1 6 2 HLA 1 HLA DSA SAB SAB LABSreen- Mixed Mixed HLA Scr LABSreen- PRA PRA Scr 67 MDSRAEB II HLA 3 17 Scr 153
MHC 2017; 24 (2) Scr Mixed Class I Ratio 1.29 1.84 Class II Ratio 0.72 3.86 Cut Off Ratio3.0 SAB CutOff nmfi1000 DQ nmfi 3000 14000 Scr PRA Class I Class II SAB Class I A2 nmfi 3000 5000 Class II DQ nmfi 3000 15000 Class I SAB 1 HLA A2 nmfi 1700 4000 Mixed Cut Off Ratio1.5 Ratio3.0 Cut Off SAB Cut Off Scr Cut Off HLA HLA HLA DSA DSA HLA DSA DSA rituximab 4 Single Antigen DSA nmfi 7814 rituximab 1000 396 DSA 1 300 3 DSA nmfi DSA 154
1 HLA MHC 2017; 24 (2) HIGH-RESOLUTION HLA TYPING BY NXTYPE TM NGS HLA TYPING KIT Seik-Soon Khor, Yuki Hitomi, Yuko Okudaira 2), Anri Masuya 2), Yuki Ozaki 3), Mayumi Ueta 4), Ken Nakatani, Masaki Nagato 5), Takahiro Ogawa 5), Chie Sotozono 4), Shigeru Kinoshita 4), Hidetoshi Inoko 2), Katsushi Tokunaga Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan 2) GenoDive Pharma Inc., Honatsugi, Kanagawa, Japan 3) The Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Osaka, Japan 4) Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan 5) Research and Development Section, Wakunaga Pharmaceutical Co., Takata, Hiroshima, Japan The human MHC region has been shown to be associated with a wide range of diseases. The recent advancement in the next generation sequencing (NGS) technology has definitely helped in increasing the resolution (up to 4-field) of HLA genotyping. However, it remains a challenge in interpreting the results from NGS platform due to biases includin-systematic sequencing error by sequencing platform, difference in the sensitivity and specificity of HLA calling algorithm, ability to resolve HLA alleles ambiguity by incorporating phasing information, and more importantly incompleteness of the current IMGT database. In order to access the sensitivity and specificity of the NXType TM NGS HLA typing kit (One Lambda), a total of 105 Japanese samples were sequenced for HLA class I genes using the Ion Torrent Personal Genome Machine (PGM) following the NXType protocol. HLA calling was performed using the HLATypeStream v1.0.0.86 with IMGT/HLA databses of 3.21.0. Concordance rates were evaluated by comparing HLATypeStream results with Luminex-based HLA typing result for up to 2-field result. With the default setting of HLATypeStream and without manual interpretation of the results, the allelic concordance is more than 98% for HLA-A, HLA-B and HLA-C. Careful inspection of the final results and occasionally manual interpretations of results are necessary especially for rare or novel HLA alleles. Long-range Short-range PCR NGS HLA PCR 3 PCR HLA short-range long-range short-range Long-range 3 HLA PCR 250 900 bp Long-range 155
MHC 2017; 24 (2) 1 HLA NGS Ion Torrent system ThermoFisher Scientific MiSeq illumina NGS HLA DNA 1 DNA phase ambiguity index barcode NGS NGS PCR 2 3 NGS PCR NGS NGS HLA KIR NK HLA KIR 150 kb 15 2 156
1 HLA MHC 2017; 24 (2) KIR NK HLA KIR KIR 157